Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Inclusion Criteria: * Age ≥18 years * ≥ 12 months and ≤ 36 months post-AlloSCT * Donor sources: matched related, matched unrelated, cord blood * Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders. * Any conditioning regimen * Any planned immunosuppressive prophylactic regimen * Patients with chronic graft-versus-host disease on stable immunosuppression * Ability to understand and the willingness to sign a written informed consent. * Negative pregnancy test in female patients of childbearing potential Exclusion Criteria: * Patients who had zoster after an allogeneic transplant and prior to enrollment * Patients who are currently pregnant * History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study. * Patients who have had a relapse of their primary hematological disease * Previous allogeneic stem cell transplantation * Acute disease at the time of vaccination * Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.